Symbols / BVS Stock $9.05 -1.63% Bioventus Inc.

Healthcare • Medical Devices • United States • NMS
BVS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Robert E. Claypoole
Exch · Country NMS · United States
Market Cap 613.12M
Enterprise Value 911.06M
Income 28.48M
Sales 576.30M
FCF (ttm) 63.31M
Book/sh 2.79
Cash/sh 0.53
Employees 940
Insider 10d —
IPO Feb 11, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 22.07
Forward P/E 9.99
PEG 1.19
P/S 1.06
P/B 3.24
P/C —
EV/EBITDA 11.26
EV/Sales 1.58
Quick Ratio 1.06
Current Ratio 1.69
Debt/Eq 123.12
LT Debt/Eq —
EPS (ttm) 0.41
EPS next Y 0.91
EPS Growth —
Revenue Growth 6.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-06
ROA 5.61%
ROE 16.46%
ROIC —
Gross Margin 68.69%
Oper. Margin 6.73%
Profit Margin 4.94%
Shs Outstand 67.75M
Shs Float 33.31M
Insider Own 11.75%
Instit Own 78.28%
Short Float 3.97%
Short Ratio 3.04
Short Interest 1.84M
52W High 11.25
vs 52W High -19.55%
52W Low 5.81
vs 52W Low 55.77%
Beta 0.67
Impl. Vol. 12.50%
Rel Volume 0.71
Avg Volume 556.59K
Volume 395.29K
Target (mean) $14.80
Tgt Median $15.00
Tgt Low $14.00
Tgt High $16.00
# Analysts 5
Recom None
Prev Close $9.20
Price $9.05
Change -1.63%
About

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.80
Mean price target
2. Current target
$9.05
Latest analyst target
3. DCF / Fair value
$16.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.05
Low
$14.00
High
$16.00
Mean
$14.80

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-22 main Barrington Research Outperform → Outperform $14
2026-03-06 main Barrington Research Outperform → Outperform $14
2026-03-06 main Craig-Hallum Buy → Buy $16
2026-02-09 init Barrington Research — → Outperform $13
2025-07-07 init Cantor Fitzgerald — → Overweight $12
2025-03-17 main Canaccord Genuity Buy → Buy $15
2024-12-17 up JP Morgan Underweight → Neutral $13
2024-11-06 main Canaccord Genuity Buy → Buy $15
2024-09-27 main Craig-Hallum Buy → Buy $17
2024-08-13 main Canaccord Genuity Buy → Buy $12
2024-08-07 main Craig-Hallum Buy → Buy $12
2024-05-08 main Canaccord Genuity Buy → Buy $8
2024-03-13 main Craig-Hallum Buy → Buy $9
2023-12-07 up Canaccord Genuity Hold → Buy $7
2023-04-03 main Craig-Hallum — → Hold $5
2022-11-30 main Goldman Sachs — → Neutral $3
2022-11-22 down Craig-Hallum Buy → Hold —
2022-11-10 main Morgan Stanley — → Overweight $5
2022-11-09 down Canaccord Genuity Buy → Hold —
2022-11-09 down JP Morgan Overweight → Underweight —
News
RSS: Latest BVS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-02 COWDY PHILIP G Director — 32,282 — —
2026-06-02 MCMURRY-HEATH MICHELLE Director — 32,282 — —
2026-06-02 NOHRA GUY P Director — 32,282 — —
2026-06-02 SUTTER MARTIN P Director and Beneficial Owner of more than 10% of a Class of Security — 32,282 — —
2026-06-02 NEELS GUIDO J Director — 32,282 — —
2026-06-02 BARTHOLDSON JOHN A Director and Beneficial Owner of more than 10% of a Class of Security — 32,282 — —
2026-06-02 STALNECKER SUSAN M Director — 32,282 — —
2026-06-02 BEYER PATRICK J Director — 32,282 — —
2026-06-02 LADONE MARY KAY Director — 32,282 — —
2026-06-02 HAWKINS WILLIAM A III Director — 39,789 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
568.09
-0.91%
573.28
+11.89%
512.35
+0.04%
512.12
Operating Revenue
568.09
-0.91%
573.28
+11.89%
512.35
+0.04%
512.12
Cost Of Revenue
179.93
-2.77%
185.05
+0.49%
184.15
+1.72%
181.04
Reconciled Cost Of Revenue
138.65
-3.15%
143.15
+5.55%
135.63
+0.18%
135.39
Gross Profit
388.16
-0.02%
388.23
+18.29%
328.19
-0.87%
331.08
Operating Expense
331.87
-9.18%
365.40
+12.03%
326.17
-10.82%
365.74
Research And Development
12.11
-13.17%
13.95
+3.76%
13.45
-43.63%
23.85
Selling General And Administration
314.03
-8.66%
343.80
+13.14%
303.88
-8.51%
332.13
Total Expenses
511.80
-7.02%
550.46
+7.86%
510.32
-6.67%
546.77
Operating Income
56.29
+146.62%
22.82
+1026.60%
2.03
+105.85%
-34.66
Total Operating Income As Reported
53.98
+455.22%
-15.20
+81.41%
-81.72
+51.13%
-167.23
EBITDA
99.21
+175.53%
36.01
+256.07%
-23.07
+81.03%
-121.61
Normalized EBITDA
101.85
+37.59%
74.03
+21.99%
60.68
+453.05%
10.97
Reconciled Depreciation
47.01
-5.13%
49.55
-13.61%
57.37
+3.55%
55.40
EBIT
52.20
+485.20%
-13.55
+83.15%
-80.44
+54.56%
-177.00
Total Unusual Items
-2.64
+93.05%
-38.02
+54.60%
-83.75
+36.83%
-132.58
Total Unusual Items Excluding Goodwill
-2.64
+93.05%
-38.02
+54.60%
-83.75
+36.83%
-132.58
Special Income Charges
-2.64
+93.05%
-38.02
+54.60%
-83.75
+36.83%
-132.58
Other Special Charges
0.33
—
—
—
Impairment Of Capital Assets
0.00
-100.00%
36.36
-53.75%
78.61
-36.96%
124.70
Restructuring And Mergern Acquisition
2.23
+63.02%
1.37
-12.06%
1.56
-80.22%
7.88
Write Off
—
—
0.00
0.00
Net Income
22.73
+162.93%
-36.12
+76.88%
-156.23
+1.56%
-158.70
Pretax Income
25.71
+149.12%
-52.34
+56.78%
-121.11
+35.93%
-189.03
Net Non Operating Interest Income Expense
-26.49
+31.72%
-38.79
+4.63%
-40.68
-238.37%
-12.02
Interest Expense Non Operating
26.49
-31.72%
38.79
-4.63%
40.68
+238.37%
12.02
Net Interest Income
-26.49
+31.72%
-38.79
+4.63%
-40.68
-238.37%
-12.02
Interest Expense
26.49
-31.72%
38.79
-4.63%
40.68
+238.37%
12.02
Other Income Expense
-4.10
+88.74%
-36.38
+55.89%
-82.46
+42.07%
-142.35
Other Non Operating Income Expenses
-1.45
-188.39%
1.65
+27.52%
1.29
+113.20%
-9.77
Tax Provision
-1.56
+70.43%
-5.29
-6327.06%
0.09
+100.19%
-44.37
Tax Rate For Calcs
0.00
+107.92%
0.00
-51.90%
0.00
-10.64%
0.00
Tax Effect Of Unusual Items
-0.55
+85.55%
-3.84
+78.17%
-17.59
+43.55%
-31.16
Net Income Including Noncontrolling Interests
27.27
+157.97%
-47.05
+75.95%
-195.62
+8.33%
-213.39
Net Income From Continuing Operation Net Minority Interest
22.73
+162.93%
-36.12
+55.84%
-81.80
+9.07%
-89.96
Net Income From Continuing And Discontinued Operation
22.73
+162.93%
-36.12
+76.88%
-156.23
+1.56%
-158.70
Net Income Continuous Operations
27.27
+157.97%
-47.05
+61.18%
-121.20
+16.21%
-144.65
Net Income Discontinuous Operations
0.00
0.00
+100.00%
-74.43
-8.28%
-68.74
Minority Interests
-4.54
-141.58%
10.92
-72.27%
39.40
-27.96%
54.69
Normalized Income
24.82
+1376.04%
-1.95
+87.56%
-15.64
-236.48%
11.46
Net Income Common Stockholders
22.73
+162.93%
-36.12
+76.88%
-156.23
+1.56%
-158.70
Diluted EPS
0.33
+163.46%
-0.52
+79.12%
-2.49
+3.86%
-2.59
Basic EPS
0.34
+165.38%
-0.52
+79.12%
-2.49
+3.86%
-2.59
Basic Average Shares
66.62
+3.21%
64.55
+3.03%
62.65
+2.05%
61.39
Diluted Average Shares
68.91
+6.77%
64.55
+3.03%
62.65
+2.05%
61.39
Diluted NI Availto Com Stockholders
22.73
+162.93%
-36.12
+76.88%
-156.23
+1.56%
-158.70
Depreciation Amortization Depletion Income Statement
5.73
-25.16%
7.65
-13.46%
8.84
-9.29%
9.75
Depreciation And Amortization In Income Statement
5.73
-25.16%
7.65
-13.46%
8.84
-9.29%
9.75
Gain On Sale Of PPE
-0.08
+72.26%
-0.29
+91.84%
-3.58
0.00
Line Item Trend 2023-12-31 2022-12-31
Total Assets
810.91
-40.92%
1,372.65
Current Assets
268.00
-1.68%
272.57
Cash Cash Equivalents And Short Term Investments
36.96
+22.45%
30.19
Cash And Cash Equivalents
36.96
+22.45%
30.19
Receivables
122.79
-9.91%
136.29
Accounts Receivable
122.79
-9.91%
136.29
Gross Accounts Receivable
127.01
-11.38%
143.32
Allowance For Doubtful Accounts Receivable
-4.22
+39.92%
-7.02
Inventory
91.33
+7.75%
84.77
Raw Materials
21.06
+14.13%
18.45
Finished Goods
70.27
+5.97%
66.31
Prepaid Assets
—
4.44
Restricted Cash
—
0.02
Assets Held For Sale Current
0.00
-100.00%
2.78
Other Current Assets
16.91
-8.83%
18.55
Total Non Current Assets
542.91
-50.65%
1,100.07
Net PPE
49.96
+13.17%
44.15
Gross PPE
90.46
+20.71%
74.94
Accumulated Depreciation
-40.50
-31.53%
-30.79
Properties
0.00
0.00
Machinery Furniture Equipment
44.20
+16.12%
38.07
Other Properties
42.50
+26.76%
33.52
Leases
3.76
+12.33%
3.35
Goodwill And Other Intangible Assets
489.81
-24.33%
647.31
Goodwill
7.46
+0.00%
7.46
Other Intangible Assets
482.35
-24.62%
639.85
Investments And Advances
—
2.64
Non Current Deferred Assets
0.00
0.00
Non Current Deferred Taxes Assets
0.00
0.00
Other Non Current Assets
3.14
-99.23%
408.62
Total Liabilities Net Minority Interest
589.79
-38.59%
960.43
Current Liabilities
175.50
-42.27%
304.02
Payables And Accrued Expenses
113.42
-5.40%
119.89
Payables
27.79
-29.24%
39.27
Accounts Payable
23.04
-37.22%
36.70
Current Accrued Expenses
85.64
+6.22%
80.62
Pensionand Other Post Retirement Benefit Plans Current
9.71
-15.04%
11.43
Total Tax Payable
4.75
+84.64%
2.57
Current Debt And Capital Lease Obligation
27.85
-15.76%
33.06
Current Debt
27.85
-15.76%
33.06
Other Current Borrowings
27.85
-15.76%
33.06
Current Deferred Liabilities
—
117.61
Other Current Liabilities
24.52
-82.44%
139.64
Total Non Current Liabilities Net Minority Interest
414.30
-36.88%
656.41
Liabilities Heldfor Sale Non Current
0.00
-100.00%
228.91
Long Term Debt And Capital Lease Obligation
367.00
-4.68%
385.01
Long Term Debt
367.00
-4.68%
385.01
Non Current Deferred Liabilities
1.21
-46.04%
2.25
Non Current Deferred Taxes Liabilities
1.21
-46.04%
2.25
Other Non Current Liabilities
46.08
+14.52%
40.24
Stockholders Equity
173.59
-46.63%
325.24
Common Stock Equity
173.59
-46.63%
325.24
Capital Stock
0.08
+1.28%
0.08
Common Stock
0.08
+1.28%
0.08
Share Issued
63.27
+1.94%
62.06
Ordinary Shares Number
63.27
+1.94%
62.06
Treasury Shares Number
0.00
0.00
Additional Paid In Capital
494.25
+0.75%
490.58
Retained Earnings
-321.54
-94.51%
-165.31
Gains Losses Not Affecting Retained Earnings
0.79
+821.82%
-0.11
Minority Interest
47.53
-45.36%
86.98
Other Equity Adjustments
0.79
+821.82%
-0.11
Total Equity Gross Minority Interest
221.12
-46.36%
412.22
Total Capitalization
540.59
-23.89%
710.25
Working Capital
92.50
+394.20%
-31.44
Invested Capital
568.44
-23.53%
743.30
Total Debt
394.85
-5.55%
418.07
Net Debt
357.88
-7.73%
387.88
Net Tangible Assets
-316.22
+1.82%
-322.07
Tangible Book Value
-316.22
+1.82%
-322.07
Interest Payable
6.61
+2944.24%
0.22
Inventories Adjustments Allowances
—
-1.85
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
74.67
+92.48%
38.80
+152.83%
15.34
+213.35%
-13.54
Cash Flow From Continuing Operating Activities
74.67
+92.48%
38.80
+121.52%
17.51
+253.53%
-11.41
Cash From Discontinued Operating Activities
0.00
0.00
+100.00%
-2.17
-1.83%
-2.13
Net Income From Continuing Operations
27.27
+157.97%
-47.05
+61.18%
-121.20
+16.21%
-144.65
Depreciation Amortization Depletion
47.01
-5.13%
49.55
-13.61%
57.37
+3.55%
55.40
Depreciation And Amortization
47.01
-5.13%
49.55
-13.61%
57.37
+3.55%
55.40
Other Non Cash Items
1.16
-72.57%
4.23
+74.48%
2.43
+62.82%
1.49
Pension And Employee Benefit Expense
—
—
0.00
0.00
Stock Based Compensation
12.67
-4.53%
13.27
+387.66%
2.72
-84.52%
17.59
Provisionand Write Offof Assets
1.26
+389.40%
-0.43
+60.65%
-1.10
-121.25%
5.19
Asset Impairment Charge
0.00
-100.00%
36.36
-53.75%
78.61
-41.76%
134.98
Deferred Tax
-0.91
+83.15%
-5.39
-126.92%
-2.38
+94.91%
-46.66
Deferred Income Tax
-0.91
+83.15%
-5.39
-126.92%
-2.38
+94.91%
-46.66
Operating Gains Losses
0.05
+42.42%
0.03
-99.22%
4.24
+184.62%
-5.01
Gain Loss On Investment Securities
—
—
—
-6.40
Net Foreign Currency Exchange Gain Loss
-0.36
-39.00%
-0.26
-138.95%
0.67
-51.92%
1.38
Change In Working Capital
-13.84
-17.49%
-11.78
-270.32%
-3.18
+89.30%
-29.73
Change In Receivables
-0.92
+91.41%
-10.67
-206.08%
10.05
+156.90%
-17.67
Changes In Account Receivables
-0.92
+91.41%
-10.67
-206.08%
10.05
+156.90%
-17.67
Change In Inventory
8.57
+152.14%
-16.43
-174.33%
-5.99
+67.82%
-18.62
Change In Payables And Accrued Expense
-19.81
-211.03%
17.85
+438.31%
-5.28
-70.22%
-3.10
Change In Other Working Capital
-1.68
+33.50%
-2.52
-28.17%
-1.97
-120.40%
9.66
Investing Cash Flow
-3.25
-114.14%
22.96
+45.27%
15.81
+113.58%
-116.44
Cash Flow From Continuing Investing Activities
-3.25
-114.14%
22.96
-15.93%
27.31
+335.56%
-11.60
Cash From Discontinued Investing Activities
0.00
0.00
+100.00%
-11.51
+89.03%
-104.84
Net PPE Purchase And Sale
-2.56
-154.67%
-1.01
+86.34%
-7.36
-398.11%
-1.48
Purchase Of PPE
-2.56
-154.67%
-1.01
+86.34%
-7.36
-398.11%
-1.48
Capital Expenditure
-2.56
-154.67%
-1.01
+86.34%
-7.36
-398.11%
-1.48
Net Investment Purchase And Sale
0.00
+100.00%
-0.71
0.00
+100.00%
-10.04
Net Business Purchase And Sale
-0.69
-102.78%
24.68
-28.83%
34.67
0.00
Purchase Of Business
-0.69
—
0.00
+100.00%
-104.84
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-1.48
Purchase Of Intangibles
—
—
0.00
+100.00%
-1.48
Net Other Investing Changes
—
—
—
-0.07
Financing Cash Flow
-62.14
-13.85%
-54.58
-104.78%
-26.65
-142.94%
62.08
Cash Flow From Continuing Financing Activities
-62.14
-13.85%
-54.58
-104.78%
-26.65
-142.94%
62.08
Net Issuance Payments Of Debt
-42.91
+27.98%
-59.58
-156.12%
-23.26
-139.02%
59.62
Issuance Of Debt
76.91
0.00
-100.00%
64.00
-38.85%
104.66
Repayment Of Debt
-119.82
-101.09%
-59.58
+31.72%
-87.26
-93.76%
-45.04
Long Term Debt Issuance
76.91
0.00
-100.00%
64.00
-38.85%
104.66
Long Term Debt Payments
-119.82
-101.09%
-59.58
+31.72%
-87.26
-93.76%
-45.04
Net Long Term Debt Issuance
-42.91
+27.98%
-59.58
-156.12%
-23.26
-139.02%
59.62
Short Term Debt Issuance
—
—
—
—
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
2.07
-15.07%
2.44
+213.88%
0.78
-86.64%
5.82
Common Stock Dividend Paid
—
—
—
0.00
Cash Dividends Paid
—
—
—
0.00
Net Other Financing Charges
-21.30
-931.54%
2.56
+161.48%
-4.17
-23.76%
-3.37
Changes In Cash
9.29
+29.35%
7.18
+59.58%
4.50
+106.62%
-67.90
Effect Of Exchange Rate Changes
0.37
+114.49%
-2.56
-507.00%
0.63
+20.73%
0.52
Beginning Cash Position
41.58
+12.49%
36.96
+16.10%
31.84
-67.91%
99.21
End Cash Position
51.24
+23.22%
41.58
+12.49%
36.96
+16.10%
31.84
Free Cash Flow
72.11
+90.83%
37.79
+373.43%
7.98
+153.16%
-15.02
Common Stock Issuance
2.07
-15.07%
2.44
+213.88%
0.78
-86.64%
5.82
Issuance Of Capital Stock
2.07
-15.07%
2.44
+213.88%
0.78
-86.64%
5.82
Sale Of Business
—
24.68
-28.83%
34.67
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category